Search

Displaying results 5591 - 5600 of 10000 in total
  1. Drug

    Bectumomab

    go.drugbank.com/drugs/DB04962
    Experimental

    Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

  2. Drug

    Dental Mesenchymal Pulp Stem Cells

    go.drugbank.com/drugs/DB15737
    Investigational

    Dental pulp is a soft, connective tissue present in the dental crown of both third molar and first premolar teeth. … They also express specific pluripotency markers like MYC and SOX2 which can be absent in other MSCs.

  3. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    ’s and Schizophrenia, an unmet medical need. … SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  4. Drug

    Tilbroquinol

    go.drugbank.com/drugs/DB13222
    Approved

    In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis. … Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467].

  5. Drug

    Vadimezan

    go.drugbank.com/drugs/DB06235
    Investigational

  6. Drug

    EPC2407

    go.drugbank.com/drugs/DB05189
    Investigational

    It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.

  7. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  8. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

  9. Drug

    Rice bran oil

    go.drugbank.com/drugs/DB11293
    ApprovedInvestigational

    Rice bran oil is classified as an indirect additive used in food contact substances by the FDA. … It contains monosaturated fatty acids, polyunsaturated fatty acids, and saturated fatty acids.

  10. Drug

    Navitoclax

    go.drugbank.com/drugs/DB12340
    Investigational

    Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. … Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies,

    Synonyms: (R)-4-(3-Morpholin-4-Yl-1-Phenylsulfanylmethyl-Propylamino)-N-(4-{4-[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-Enylmethyl]-Piperazin-1-Yl}-Benzoyl)-3-Trifluoromethanesulfonylbenzenesulfonamide